Aurobindo Pharma on Thursday reported a 10 per cent year-on-year (Y-o-Y) drop in consolidated profit after tax (PAT) for the ...

Aurobindo Pharma’s Q3 net profit declined 10% YoY to Rs 846 crore, despite record revenue of Rs 7,979 crore. US sales ...

Ahead of earnings announcement, shares of Aurobindo Pharma ended the trading session flat at ₹1,184.50 apiece on the BSE, ...

The Hyderabad-based bulk and generic drug maker's net profit fell 9.7% year-on-year to Rs 846 crore in the quarter ended Dec.

Telangana: Aurobindo Pharma has announced that the Company will be investing Rs.10.40 crores to acquire 26 percent equity and ...

Aurobindo Pharma reported a 10% YoY decline in net profit to Rs 846 crore for Q3FY25, mainly due to a decrease in US sales.

Hyderabad: Degrowth in its US formulations business dragged down Aurobindo Pharma's consolidated net profits for the third ...

HYDERABAD: Degrowth in its US formulations business dragged down Aurobindo Pharma’s consolidated net profits for the third ...

Aurobindo Pharma's net profit fell 10% to Rs 846 crore in Q3 FY25, while revenue rose to Rs 7,979 crore. The company attributes this to volume growth and new launches.

Six leading pharmaceutical companies, Sun Pharmaceutical Industries, Ipca Laboratories, Indoco Remedies, Aurobindo Pharma, ...

Quarterly Net Profit at Rs. 845.81 crore in December 2024 down 9.66% from Rs. 936.29 crore in December 2023. EBITDA stands at ...